ESR1 and breast carcinoma: Anti-estrogen therapy is one of the therapeutic choices for estrogen receptor-positive (ER+ve) breast cancer; however; 20–40% of ER+ve tumors acquired resistance to anti-estrogen therapy through multiple mechanisms113.